focus -WSS

focus

author：comprehensive 2025-09-27 16:23:42 - browse：5242

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Key Senate committee drafts bipartisan bill to stem drug shortages

focus

entertainment

WSS

Dogs on Prozac: What pet anti

Focused ultrasound for uterine fibroids: an uphill battle

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

First Opinion Podcast: What happens when kids become caregivers?

Startling documents reveal new facets of Sacklers' opioid empire

Close Medicare's dangerous gaps in addiction treatment coverage

focus

focus

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Hepatitis C has a cure — but many Americans still lack access to it

Report: NIH

Drug repurposing or repositioning? The language matters

Do more moles mean more problems? Not so, says new study

Heart attack and stroke risk calculators need revising

Latest bird flu infection made farmworker sicker than earlier cases

Dobbs anniversary: the lost opportunity of abortion as health care

Element Biosciences CEO lays out genome sequencing strategy

explore

AI used to predict Covid

Orangutan used medicinal plant to treat wound, first time ever seen

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Prosthetic arm enables patients to feel the objects they grip

MassMutual is introducing free genetic testing for members

entertainment

focus

entertainment

focus